Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding

(2018) Emilie M.J. van Brummelen et al.   Oncotarget

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses

(2018) Nicolle H. Rekers et al.   OncoImmunology

Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses

(2017) Byron H. Kwan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

(2017) Christian Klein et al.   OncoImmunology

In SituTumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments

(2016) Zachary S. Morris et al.   CANCER RESEARCH

Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing  -Irradiation

(2016) M. Hettich et al.   CANCER RESEARCH

Immunocytokines for cancer treatment: past, present and future

(2016) Dario Neri et al.   CURRENT OPINION IN IMMUNOLOGY

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

(2016) N. Arenas-Ramirez et al.   Science Translational Medicine

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers

(2016) Michael Hettich et al.   Theranostics

Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging

(2016) S. V. Hartimath et al.   OncoImmunology

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms

(2015) Jamie B. Spangler et al.   IMMUNITY

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

(2015) Michel M van den Heuvel et al.   Journal of Translational Medicine

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

(2015) Alice Tzeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-2: Biology, Design and Application

(2015) Natalia Arenas-Ramirez et al.   TRENDS IN IMMUNOLOGY

Role of Local Radiation Therapy in Cancer Immunotherapy

(2015) Sandra Demaria et al.   JAMA Oncology

Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

(2015) C. M. L. Zegers et al.   CLINICAL CANCER RESEARCH

Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer

(2014) Rodney A Rosalia et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Noninvasive positron emission tomography and fluorescence imaging of CD133+tumor stem cells

(2014) Simone Gaedicke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

PET Imaging of Inflammation Biomarkers

(2013) Chenxi Wu et al.   Theranostics

N-(4-18F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes

(2012) V. Di Gialleonardo et al.   JOURNAL OF NUCLEAR MEDICINE

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2--Tumor and Immunological Responses

(2012) S. K. Seung et al.   Science Translational Medicine

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor   subunit CD25

(2010) S. Letourneau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy

(2009) J. Tomala et al.   JOURNAL OF IMMUNOLOGY